Lonza, a leading supplier to the global specialty ingredient market, has acquired Capsugel for USD $5.5 billion. According to the company, the acquisition follows Lonza’s strategy to accelerate growth and deliver value along the healthcare continuum.
With the acquisition of Capsugel, Lonza says it has gained a trusted brand with a large breadth of technologies. This will allow it to expand the market reach of its contract development and manufacturing organization (CDMO) and products businesses.
Overall, this move was carried out to create a leading integrated, value-added solutions provider in drug development, formulation, delivery technologies and manufacturing for the global pharma and consumer healthcare industries. According to Lonza, the combined business will support the evolving needs of the industry. It will provide additional value by offering an integrated portfolio of industry-leading technologies, from active pharmaceutical ingredients (APIs) through excipients to dosage forms and delivery technologies.
